Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Secures $16M Debt Facility

NEW YORK (GenomeWeb) – HTG Molecular Diagnostics today announced the closing of a growth capital term loan facility for up to $16 million with Silicon Valley Bank and Oxford Finance.

HTG said it drew $11 million of the funding at the initial closing.

In February, the Tucson, Ariz.-based firm closed a Series E preferred stock offering for an undisclosed amount. In a statement today, HTG CEO TJ Johnson said, "Together with the capital raised through recent equity offerings, the debt facility with SVB/Oxford provides HTG the funding needed to pursue several operating initiatives, including key research and development programs and strategic sales and marketing expansion."

The RNA-based testing firm launched its first next-generation sequencing-based assay in June, which targets and sequences 2,275 microRNAs using proprietary nuclease protection probe technology. Johnson told In Sequence at the time that the panel is the first of several NGS-based assays in HTG's pipeline and that the company eventually will move into DNA-based assays.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.